Clinical remissions in previously untreated patients with follicular lymphoma after intradermal immunization with a recombinant idiotype vaccine

被引：0
|
作者：
Mikesch, K [1 ]
Bertinetti, C [1 ]
Veelken, H [1 ]
机构：
[1] Univ Freiburg, Med Ctr, D-7800 Freiburg, Germany
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
118
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [31] Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma
    Magnano, L.
    Balague, O.
    Dlouhy, I.
    Rovira, J.
    Karube, K.
    Pinyol, M.
    Rivas-Delgado, A.
    Costa, D.
    Martinez-Trillos, A.
    Gonzalez-Farre, B.
    Martinez-Pozo, A.
    Gine, E.
    Colomer, D.
    Delgado, J.
    Villamor, N.
    Campo, E.
    Lopez-Guillermo, A.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2799 - 2805
  • [32] Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients
    Courter, SG
    Bedrosian, CL
    SEMINARS IN HEMATOLOGY, 2001, 38 (02) : 52 - 59
  • [33] Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients
    Lusher, JM
    VOX SANGUINIS, 1999, 77 : 9 - 9
  • [34] Erratum to: Clinical evaluation of a recombinant factor VIII preparation (kogenate) in previously untreated patients with hemophilia A
    A. Yoshioka
    K. Fukutake
    J. Takamatsu
    A. Shirahata
    International Journal of Hematology, 2004, 79 : 205 - 205
  • [35] Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α
    Smyth, Liam
    Buckstein, Rena
    Nancy, Pennell
    Weerasinghe, Rashmi
    Cheung, Matthew
    Piliotis, Eugenia
    Imrie, Kevin
    Spaner, David
    Reis, Marciano D.
    Chodirker, Lisa
    Ghorab, Zeina
    Ruth, Violet
    Milliken, Nancy
    Boudreau, Angela
    Berinstein, Neil
    BLOOD, 2017, 130
  • [36] Biological and clinical responses after intradermal and intravenous administrations of mature dendritic cells loaded with tumor lysate in follicular lymphoma patients.
    Baudard, Marion
    Conge, Anne Marie
    Veyrune, Jean-Luc
    Condomines, Maud
    Klein, Bernard
    Rossi, Jean-Francois
    BLOOD, 2006, 108 (11) : 387B - 387B
  • [37] OBINUTUZUMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: AN IMPORTANT CLINICAL AND COST-EFFECTIVE OPTION FOR HIGH-RISK (INTERMEDIATE/HIGH FLIPI) PATIENTS IN CANADA
    Mistry, B.
    Launonen, A.
    Tsuchiya, C.
    Cameron, H.
    Thuresson, P. O.
    VALUE IN HEALTH, 2019, 22 : S75 - S75
  • [38] CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
    Martin, Peter
    Jung, Sin-Ho
    Johnson, Jeffrey L.
    Pitcher, Brandy
    Elstrom, Rebecca L.
    Bartlett, Nancy
    Blum, Kristie A.
    Richards, Kristy L.
    Leonard, John
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
    Fenghua Gao
    Tingting Zhang
    Hengqi Liu
    Wei Li
    Xianming Liu
    Lihua Qiu
    Lanfang Li
    Shiyong Zhou
    Zhengzi Qian
    Sitong Dong
    Sai Zhao
    Xianhuo Wang
    Huilai Zhang
    Annals of Hematology, 2022, 101 : 2383 - 2392
  • [40] Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Thuresson, Per-Olof
    Li, Jia
    Reyes, Carolina M.
    Veenstra, David
    BLOOD, 2017, 130
12345